Asthma: key endpoint results by drug
The key endpoints of Asthma trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Asthma page.
Severe exacerbations, annualised rate
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| albuterol / budesonide | 0.5 | 0.6 (AS MDI) | — | 80/180 μg · n 1054 | NCT03769090 Phase 3, secondary |
| Benralizumab | 0.9 | 1.9 | −0.9 | wk 24 · n 427 | NCT03170271 Phase 3, primary |
| Budesonide/glycopyrrolate/formoterol fumarate | 0.5 | 0.6 (budesonide/formoterol fumarate) | — | 320/14.4/9.6 μg BID · wk 52 · n 725 | NCT04609878 Phase 3, primary |
| Depemokimab | 0.6 | 1.1 | −0.5 | wk 52 · n 252 | NCT04718103 Phase 3, primary |
| dupilumab | 0.5 | 1.0 | −0.4 | 300 mg q2w · wk 52 · n 633 | NCT02414854 Phase 3, primary |
| Fluticasone propionate/salmeterol (Advair HFA) | 1.9 | 2.1 (Fluticasone Propionate) | — | 250/50 mcg BID · wk 52 · n 306 | NCT00452699 Phase 4, secondary |
| Mepolizumab | 0.5 | 1.3 | −0.9 | 100 mg · wk 52 · n 149 | NCT03562195 Phase 3, primary |
| risankizumab | 1.6 | 1.4 | +0.2 | wk 24 · n 105 | NCT02443298 Phase 2, secondary |
| tezepelumab | 0.9 | 2.1 | −1.2 | 210mg Q4W · wk 52 · n 528 | NCT03347279 Phase 3, secondary |
| tralokinumab | 0.6 | 0.6 | ±0 | 300 mg Q2W · wk 52 · n 398 | NCT02161757 Phase 3, primary |
Drugs checked with no result here: 36 not reported, 15 not posted, 12 trial running.
Trough FEV1, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| albuterol (Ventolin) | 0.1 | 0.0 (ADVAIR DISKUS) | — | 200 mcg · wk 26 · n 120 | NCT02175771 Phase 3, secondary |
| albuterol / budesonide | 0.1 | 0.0 | +0.1 | 160/180 μg · wk 12 · n 197 | NCT03847896 Phase 3, primary |
| Beclomethasone dipropionate/formoterol fumarate | 0.2 | 0.1 (CHF 718 pMDI) | — | 800/24 µg total daily dose · wk 12 · n 274 | NCT05292586 Phase 3, secondary |
| Benralizumab | 0.4 | 0.2 | +0.1 | 30 mg q.4 Weeks · wk 48 · n 236 | NCT01928771 Phase 3, secondary |
| Budesonide / formoterol fumarate (SYMBICORT) | 0.2 | 0.1 (Budesonide) | — | wk 12 · n 150 | NCT00702325 Phase 4, primary |
| Budesonide/glycopyrrolate/formoterol fumarate | 0.1 | 0.1 (budesonide/formoterol fumarate) | — | 320/14.4/9.6 μg BID · wk 24 · n 330 | NCT04609878 Phase 3, secondary |
| Depemokimab | 0.2 | 0.2 | +0.1 | wk 52 · n 239 | NCT04718103 Phase 3, secondary |
| dupilumab | 0.1 | 0.5 | −0.3 | wk 24 · n 13 | NCT03560466 Phase 3, secondary |
| Fluticasone Furoate | 0.2 | 0.0 | +0.1 | 100 µg OD · wk 24 · n 111 | NCT01159912 Phase 3, primary |
| fluticasone furoate/umeclidinium/vilanterol | 0.1 | 0.1 (FF/VI) | — | 100/31.25/25 mcg · wk 24 · n 399 | NCT02924688 Phase 3, primary |
| fluticasone furoate/vilanterol | 0.4 | 0.2 | +0.2 | 100/25 µg OD · wk 12 · n 200 | NCT01165138 Phase 3, primary |
| Fluticasone propionate/salmeterol (Advair Diskus) | 0.1 | 0.1 (FF/VI) | — | 100/31.25/25 mcg · wk 24 · n 399 | NCT02924688 Phase 3, primary |
| Glycopyrronium (PT001) | 0.1 | 0.1 | ±0 | 28.8 μg · wk 24 · n 196 | NCT03358147 Phase 2/3, secondary |
| indacaterol maleate / mometasone furoate | 0.1 | -0.1 | +0.2 | wk 0.14 · n 36 | NCT00557440 Phase 2, primary |
| Olodaterol | 0.1 | 0.0 | +0.1 | 20 mcg qd · wk 4 · n 61 | NCT00467740 Phase 2, primary |
| risankizumab | -0.1 | -0.0 | ±0 | wk 24 · n 105 | NCT02443298 Phase 2, secondary |
| Tiotropium bromide | 0.1 | -0.0 | +0.2 | 2.5 mcg once daily · wk 24 · n 247 | NCT01172808 Phase 3, primary |
| Umeclidinium | 0.3 | 0.1 | +0.2 | 31.25 mcg QD · wk 24 · n 136 | NCT03012061 Phase 2, primary |
| Vilanterol | 0.3 | 0.1 | +0.1 | 25 µg · wk 4 · n 99 | NCT00600171 Phase 2, primary |
Drugs checked with no result here: 34 not reported, 13 not posted, 7 trial running.
ACQ-5, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Benralizumab | 0.2 | 0.1 (benralizumab) | — | wk 32 · n 112 | NCT04159519 Phase 4, secondary |
| Depemokimab | -0.8 | -0.7 | −0.1 | wk 52 · n 246 | NCT04718103 Phase 3, secondary |
| dupilumab | -1.4 | -1.1 | −0.3 | 300 mg q2w · wk 12 · n 633 | NCT02414854 Phase 3, secondary |
| fluticasone furoate/vilanterol | -1.2 | -1.1 (FF) | — | wk 24 · n 385 | NCT03248128 Phase 3, secondary |
| Glycopyrronium (PT001) | -0.9 | -0.9 | +0.1 | 28.8 μg · wk 24 · n 195 | NCT03358147 Phase 2/3, secondary |
| Mepolizumab | -0.8 | -0.4 | −0.4 | 100 mg · wk 24 · n 266 | NCT02281318 Phase 3, secondary |
Drugs checked with no result here: 38 not reported, 18 not posted, 11 trial running.
OCS dose reduction
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Benralizumab | 75% | 25% | +50 | 30 mg q.4 Weeks · wk 28 · n 72 | NCT02075255 Phase 3, primary |
| dupilumab | 70.1% | 41.9% | +28.2 | 300 mg q2w · wk 24 · n 103 | NCT02528214 Phase 3, primary |
| Mepolizumab | -50% | 0% | −50 | 100 mg SC · wk 24 · n 69 | NCT01691508 Phase 3, secondary |
| tralokinumab | -37.6% | -29.9% | −7.8 | wk 40 · n 70 | NCT02281357 Phase 3, primary |
Drugs checked with no result here: 38 not reported, 18 not posted, 13 trial running.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 73 approved or late-stage drugs with a featured trial in Asthma were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.